Puretech’s cautionary tale about pivotal study read-across
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
Restorbio clutches at straws, and investors say that’s fine
The win Restorbio is claiming in a mid-stage study is by no means clear-cut.
Upcoming events – Tocagen’s brain cancer data and Restorbio tackles respiratory infections
Mid-stage data for Tocagen and Restorbio are approaching.
First-quarter floats hold amid uncertain climate
Biotech IPOs record another strong quarter, setting the pace for a bumper year of new issues.
